# OCT macular changes in type 1 ROP following Ranibizumab injections

## TL;DR

This study examines how Ranibizumab injections affect macular changes in preterm infants with type 1 ROP using OCT imaging.

## Contribution

The study reveals significant outer retinal layer thickening and differentiation after Ranibizumab treatment in type 1 ROP infants.

## Key findings

- Significant increase in outer retinal layer thickness was observed one month after Ranibizumab injections.
- Macular edema was present in 50% of eyes and associated with smaller birth weight.
- Regression of plus disease was linked to lower central full thickness at one week and one month.

## Abstract

To investigate the OCT macular changes in type 1 ROP one month following Ranibizumab injections.

Preterm infants with type 1 ROP indicated for Ranibizumab injections were included in this study. Handheld OCT imaging was performed at baseline, 1 week, and 1 month post injection. Central full thickness (CFT), inner retinal layer (IRL), and outer retinal layer (ORL) thickness measurements were taken from foveal center and parafoveal region.

24 eyes of 12 infants were included in this study. There were no significant changes in the mean CFT and IRL thickness at 1 month (p = 0.5 and 0.1 respectively). However, there was significant increase in the mean ORL thickness at 1 month (69.9 ± 16, 96.1 ± 25 at baseline and one month respectively, p < 0.001), with differentiation (appearance of IS/OS junction ± ELM) in 55.6% of eyes. Macular edema (ME) was observed in 12 eyes (50%) and was associated with smaller birth weight (p = 0.0290). There was no significant decrease in mean CFT in eyes with ME at 1 month (p = 0.13), with complete resolution in only 6 eyes (50%) during the study period. Regression of plus was associated with lower CFT (1 week and 1 month; p = 0.02 and 0.03, respectively).

Ranibizumab treated eyes in type 1 show ORL thickening and differentiation but with inadequate resolution of ME.